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Background
Enhancing tumor-directed immune responses has emerged
as an important therapeutic approach to many cancers.
Th17/Tc17 cells can mediate robust anti-tumor responses
in rodent models and are associated with improved prog-
nosis in some human cancers. RORgt is the key transcrip-
tion factor controlling the development and function of
these cells by supporting the expression of pro-inflamma-
tory cytokines and survival genes while reducing expres-
sion of co-inhibitory receptors such as PD-1.
Methods
To enhance the function of anti-tumor Type 17 T cells,
small molecule RORg agonists were designed. These
synthetic agonists, when present during murine and
human T cell activation in vitro, increase production of
IL-17A and other cytokines/chemokines, and improve cell
survival after resting or re-activation.
Results
This improved survival translates to a potent and durable
anti-tumor response as adoptive cell therapy using RORg
agonist-treated T cells significantly reduces growth of
established B16F10 and EG.7 tumors compared to
untreated cells. Up to 71 days post transfer, more donor
T cells can be recovered from spleens and tumors of mice
receiving RORg agonist-treated cells. These cells maintain
elevated IL-17 production and reduced co-inhibitory
receptor expression suggesting that RORg agonist-induced
changes are long-lasting. Interestingly, tumor-specific
T cells recovered from mice receiving agonist-treated cells
expressed central memory (CD44+CD62L+) or stem-like
(CD44-CD62L+) markers vs. the predominantly effector
(CD44+CD62L-) cells recovered from animals receiving
untreated T cells. In separate experiments, oral adminis-
tration of RORg agonists significantly inhibits the growth
of subcutaneous MC38 and 4T1 tumors in an immune-
dependent manner with significantly increased RORg and
IL-17 expression in tumors consistent with an increased
survival or recruitment of type 17 cells.
Conclusions
By enhancing cytokine production, decreasing co-inhibi-
tory receptor expression while promoting long term survi-
val and self-renewal of T cells, RORg agonists represent a
promising immunotherapy approach for the treatment of
cancer.
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